Bluebird Bio (BLUE)
$2.96
0.08 (2.63%)
BLUE Stock Quote Delayed 30 Minutes
7 Very Oversold Nasdaq Stocks to Buy Right Now
The worries that have pushed the Nasdaq down sharply are overdone. Here are seven oversold Nasdaq stocks poised to rebound.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
200.03M
PE Ratio
-3.36
EPS
-0.88
Volume (Avg. Vol.)
448,448
Day's Range
$2.96 - $3.05
52-Week Range
$2.78 - $8.58
Dividend & Yield
N/A (N/A)
BLUE Stock Predictions, Articles, and Bluebird Bio News
Why Is Bluebird Bio (BLUE) Stock Down 9% Today?
Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment.
Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval
The Boston-based biotech company has secured FDA approval for one of its gene therapies. Let's take a closer look at BLUE stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them!
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy
Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving!
Bluebird (BLUE) Stock Soars 25% Following 2 FDA Recommendations
Bluebird Bio (BLUE) stock is gaining on Monday following positive news last week from an advisory committee set up by the FDA.
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way.
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! Let's get right into it with an overview of the biggest pre-market stock movers for Monday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday!
Upcoming IPOs This Week: Vita Coco, Portillo’s and 8 More New Stocks to Watch
There's upcoming IPOs this week that traders are going to want to keep an eye on and we're helping out with a handy list for investors.
